A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Phase 2
90
about 2.1 years
18+
13 sites in AZ, CA, FL +7
What this study is about
This trial is testing a treatment called PCS6422 with capecitabine (Cap) compared to standard dose of Cap alone for people with advanced or metastatic breast cancer. The goal is to see if PCS6422 + Cap is an effective and safe treatment option for those who can't have anthracycline- or taxane-containing therapies, or other available therapies like PD-1 or PARP inhibitors.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Capecitabine
- 2.Take PCS6422 and capecitabine
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
capecitabine
oral (Oral Tablet)
Primary: Evaluation of Objective Response Rate (ORR), Number of patients with adverse events (AEs)
Secondary: Evaluation of Disease Control Rate (DCR), Evaluation of Duration of Response (DOR), Evaluation of Progression Free Survival (PFS)
Oncology